Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

@article{Gordon2018EfficacyAS,
  title={Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials},
  author={Kenneth B. Gordon and Bruce Strober and Mark G. Lebwohl and Matthias Augustin and Andrew Blauvelt and Yves Poulin and Kim A. Papp and Howard Sofen and Llu{\'i}s Puig and Peter Foley and Mamitaro Ohtsuki and Mary Flack and Ziqian Geng and Yihua Gu and Joaquin Mario Valdes and Elizabeth H.Z. Thompson and Herv{\'e} Bachelez},
  journal={The Lancet},
  year={2018},
  volume={392},
  pages={650-661}
}

Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial

Both doses of risankizumab were superior to placebo in treating patients with moderate to severe plaque psoriasis and the safety profile was consistent with previous risankIZumab trials, with no new or unexpected safety findings.

Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial

Risankizumab treatment results in significantly greater improvement of signs and symptoms of PsA compared with placebo and is well tolerated in patients with active PsA who have responded inadequately or are intolerant to ≥1 conventional synthetic disease-modifying antirheumatic drug (csDMARD).

Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines

Risankizumab has shown promising results in the control of psoriasis in the long-term, with a high percentage of patients (>80%) maintaining PASI 90 and PASi 100 up to 52 weeks of treatment.

Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials

The results demonstrate 80 mg ixekizumab maintains long-term efficacy and a safety profile consistent with previous data in patients with moderate-to-severe plaque psoriasis through 5 years of treatment.

Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials

The objective was to evaluate the long-term efficacy and safety of ixekizumab in moderate-to-severe plaque psoriasis through 5 years and to exclude patients who escalated to every-2-week dosing.

Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial

Treatment with risankizumab resulted in significant improvements versus placebo in key disease outcomes and was well tolerated in patients with PsA who were Bio-IR and/or csDMARD-IR.

Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial

Risankizumab treatment was well tolerated with sustained clinical efficacy for at least 48 weeks and all efficacy results were consistent or slightly increased at OLE week 48 compared with week 12.

Safety and Efficacy of Risankizumab and Infliximab in the Treatment of Plaque Psoriasis: Results From a Direct and Indirect Meta-Analysis

Risk ratios showed that risankizumab is preferred for the treatment of psoriasis than infliximab, and is significantly more effective and safe.
...

References

SHOWING 1-10 OF 28 REFERENCES

Risankizumab versus Ustekinumab for Moderate‐to‐Severe Plaque Psoriasis

In this phase 2 trial, selective blockade of interleukin‐23 with risankizumab was associated with clinical responses superior to those associated with ustekinumab, and this trial was not large enough or of long enough duration to draw conclusions about safety.

Efficacy of Immunobiologic and Small Molecule Inhibitor Drugs for Psoriasis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

The anti-IL-17 drugs brodalumab, ixekizumab and secukinumab showed an equal or greater chance of helping patients achieve a 75% improvement on PASI compared with other reviewed drugs.

The role of IL 23 in the treatment of psoriasis

  • L. Puig
  • Biology, Medicine
    Expert review of clinical immunology
  • 2017
Specific IL-23p19 blockade with high-affinity monoclonal antibodies seems to be able to induce long-term remissions of the activity in psoriasis and might eventually represent a paradigm change in the treatment of psorosis.

PASI90 response: the new standard in therapeutic efficacy for psoriasis

  • L. Puig
  • Medicine, Psychology
    Journal of the European Academy of Dermatology and Venereology : JEADV
  • 2015
Initial data suggest that the PASI90 benchmark provides better discriminatory value as regards achievement of DLQI = 0–1 response, and further research is required to confirm the value of absolute PASi cut‐offs as a measure of therapeutic success independent of baseline and duration of treatment.

Shifting the focus – the primary role of IL‐23 in psoriasis and other inflammatory disorders

Recent developments leading to the current understanding of the key role of IL‐23 as a ‘master regulator’ of autoimmune inflammation and the clinical evidence for agents that specifically target this modulator in the context of treating psoriasis, spondyloarthropathy and inflammatory bowel disease are described.